Personalis, Inc.
NASDAQ:PSNLMedical - Diagnostics & Research
+$0.34 today
- Market cap
- $1.62B
- Beta
- 2.28
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$0.92
Volume 1.47M
Average 2.31M
PSNL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Personalis, Inc.NASDAQ: PSNL
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $2.55M rose 15.1% year over year, ahead of the -4.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 11.1% from the prior quarter. Over 3 fiscal years it compounded at -21.4% a year.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +15.1% holds above the trailing-twelve-month pace of -4.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.43M USD
- Year-over-year change
- -11.8%
- 4-year CAGR
- -10.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.43M | -11.8% |
| FY2024 | 2024-12-31 | 10.69M | -23.9% |
| FY2023 | 2023-12-31 | 14.05M | -27.7% |
| FY2022 | 2022-12-31 | 19.43M | +35.2% |
| FY2021 | 2021-12-31 | 14.38M | — |
Stock-Based Compensation vs competitors
How PSNL compares with its peers on the latest reported figures
- PSNL's LTM Mar 2026 stock-based compensation of $9.76M is the 9th largest of the 10 companies compared; the peer median is $32.2M.
- Its year-over-year change of -4.5% is the 5th highest of 9, against a peer median of -4.4%.
- Stock-based compensation amounts to 15.1% of revenue for PSNL, versus a peer median of 7.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $381.42M | +21.6% | +32.5% | 14.1% | |
| LTM Sep 2026 | $210.96M | +32.4% | +20.6% | 16.5% | |
| LTM Jun 2026 | $48.51M | +20.3% | +17.7% | 8.6% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $35.7M | +95.3% | -8.5% | 7.9% |
| LTM Mar 2026 | $32.2M | -31.9% | -2.6% | 3.9% | |
| LTM Mar 2026 | $29.03M | -33.3% | +6.6% | 9.1% | |
| LTM Jun 2026 | $28.16M | -29.2% | +18.8% | 3.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $25.54M | — | — | 6.4% |
| LTM Mar 2026 | $9.76M | -4.5% | -21.4% | 15.1% | |
| LTM Jun 2026 | $5.97M | -90.3% | -8.4% | 3.6% | |
| Peer median (excluding PSNL) | $32.2M | -4.4% | +12.2% | 7.9% | |
Competitors are the stored peer set for PSNL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (65.23M) | (113.32M) | (108.3M) | (81.28M) | (81.27M) |
| Depreciation & Amortization | 6.01M | 8.43M | 11.3M | 10.94M | 10.05M |
| Deferred Income Tax | 2.03M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.38M | 19.43M | 14.05M | 10.69M | 9.43M |
| Change in Working Capital | (31.14M) | 10.61M | 13.48M | (2.59M) | (10.19M) |
| Accounts Receivables | (12.12M) | 1.83M | (1.09M) | 9.59M | (8.06M) |
| Inventory | 29K | (2.98M) | (1.93M) | 4.43M | (204K) |
| Accounts Payables | (1.46M) | 3.09M | 5.18M | (8.92M) | 4.55M |
| Other Working Capital | (17.6M) | 8.68M | 11.33M | (7.68M) | (6.48M) |
| Other Non-Cash Items | 3.12M | 4.61M | 13.21M | 17.1M | (2.96M) |
| Operating Cash Flow | (70.83M) | (70.23M) | (56.26M) | (45.15M) | (74.95M) |
| Capital Expenditures | (11.08M) | (49.9M) | (10.91M) | (1.6M) | (4.5M) |
| Acquisitions (Net) | 48.99M | 0 | (24.01M) | 0 | 0 |
| Purchases of Investments | (267.13M) | (121.49M) | (103.95M) | (121.71M) | (210.17M) |
| Sales of Investments | 218.14M | 223.92M | 127.96M | 88M | 192.11M |
| Other Investing Activities | (48.99M) | 0 | 24.01M | 242K | 0 |
| Investing Cash Flow | (60.07M) | 52.54M | 13.1M | (35.07M) | (22.57M) |
| Debt Repayment | 3.31M | (1.1M) | 174K | (1.13M) | 585K |
| Common Stock Issued | 162.26M | 0 | 3.51M | 97.82M | 129.94M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.13M | 2.47M | 7.34M | 17.98M | (189K) |
| Financing Cash Flow | 169.7M | 1.37M | 11.03M | 114.67M | 130.34M |
| Effect of Forex Changes | 47K | (127K) | (16K) | (22K) | 6K |
| Net Change in Cash | 38.85M | (16.46M) | (32.14M) | 34.43M | 32.83M |
| Free Cash Flow | (81.91M) | (120.13M) | (67.17M) | (46.75M) | (79.45M) |
Personalis, Inc.
NASDAQ:PSNL
Intrinsic Alpha fair value
Locked
Current Price
$14.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.